Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis
Status:
Active, not recruiting
Trial end date:
2020-05-01
Target enrollment:
Participant gender:
Summary
In a Phase 2 Simon's Optimal Two-Stages Design intravenous tocilizumab will be administered
as single 8mg/Kg dose in patients affected by severe multifocal interstitial pneumonia
correlated to SARS-CoV2 infection. Aim of the study is to test the hypothesis that an
anti-IL6 treatment can be effective in calming the virus-induced cytokine storm, blocking
deterioration of lung function or even promoting a rapid improvement of clinical conditions,
preventing naso-tracheal intubation and/or death.